The Lincoln Project isn't going anywhere.
The PAC of President Trump-opposing Republicans and other moderates has built a social media behemoth based largely on trolling the president with pointed ads. And once it potentially achieves its goal of getting Joe Biden and other Democrats elected, it's looking to capitalize on that and build a whole media empire, Axios reports.
The Lincoln Project's Twitter account boasts a following that even exceeds the Republican party's, and has raked in millions of dollars from its supporters who'd like to see Trump out of the White House. To Ra Kumar, the project's representative at United Talent Agency, it's clear that "they know how to get audiences," he tells Axios.
So in the coming weeks, the Lincoln Project is expected to move beyond podcasts and TV ads and into Hollywood. For starters, the group is working with a documentarian to produce a non-fiction film after the election, Axios reports. Some TV networks are interested in running the project's livestreamed shows, a source says. TV studios are also reportedly reaching out to work with the Lincoln Project "to help develop a House of Cards-like fiction series," Axios reports — a comparison that probably doesn't help the project with allegations of stealing ideas and memes. Kathryn Krawczyk
Flu shots are already considered an important factor in combating the coronavirus pandemic, since widespread inoculations will hopefully help prevent medical facilities from becoming overwhelmed by dual diseases. But new research suggests flu shots may also play some role in preventing COVID-19 infections in the first place, The Scientific American reports.
A study, which has not yet been peer-reviewed, found that workers at Radboud University Medical Center in the Netherlands who received a flu shot during the 2019-20 season were 39 percent less likely than their colleagues to test positive for the coronavirus as of June 1, 2020. Non-vaccinated employees contracted the virus at a 2.23 percent rate, compared to only 1.33 percent of those who were vaccinated.
The preliminary research would certainly require further clinical trials — though the author of the study noted it would be unethical to compel a control group of subjects to be denied a flu shot — and there could be several reasons why the vaccinated group staved off infection more easily, including the possibility that they are generally more health conscious and took more COVID-19 precautions.
Still, there have been other studies that hint at a possible link between flu shots (and other vaccines, for that matter) and lower COVID-19 risk. Additionally, the Radboud research team conducted a laboratory experiment in which they took blood cells from healthy individuals, purified them, and exposed some of them to a flu vaccine. After allowing the cells to grow for a few days, the researchers exposed them to the coronavirus. A day later they found that the vaccinated cells produced more of several kinds of immune molecules that fight off pathogens than those that were initially left alone. Read more at The Scientific American. Tim O'Donnell
Researchers in the United Kingdom say they've observed a "significant" decline in the percentage of the population with COVID-19 antibodies, potentially pointing to "waning immunity."
Imperial College London scientists in the study found the prevalence of COVID-19 antibodies declined from six percent of the British population in June to 4.4 percent in September, Reuters reports. They came to the conclusion that there has been a "significant decline in the proportion of the population with detectable antibodies" by sending out finger-prick tests to a randomly selected group of over 365,000 people in England, according to CNN.
"On the balance of evidence I would say, with what we know for other coronaviruses, it would look as if immunity declines away at the same rate as antibodies decline away, and that this is an indication of waning immunity at the population level," Wendy Barclay, head of Imperial College London's Department of Infectious Disease, said, per Reuters.
The researchers were specifically looking for IgG antibodies in the study, and CNN notes that some other research has suggested "that other types of antibodies may persist longer than IgG does."
But Imperial College London's Helen Ward told BBC News the study suggests that "immunity is waning quite rapidly." Ward added in a statement, "We don't yet know whether this will leave these people at risk of reinfection with the virus that causes COVID-19, but it is essential that everyone continues to follow guidance to reduce the risk to themselves and others." Brendan Morrow
The U.S. National Institutes of Health on Monday ended one clinical trial of Eli Lilly's experimental COVID-19 antibody treatment after finding that the drug, "bamlanivimab, is unlikely to help hospitalized COVID-19 patients recover from this advanced stage of their disease." The trial was suspended Oct. 13 out of "an abundance of caution," but the NIH said Monday it had found no significant safety issue with the monoclonal antibody treatment.
Eli Lilly said it will continue testing bamlanivimab with the NIH on mild or moderately ill COVID-19 patients to see if it reduces hospitalizations and severe symptoms. Eli Lilly is also conducting its own separate trials.
Human bodies make antibodies to fight off infections, and Eli Lilly's experimental drug, like a similar treatment from Regeneron, features concentrated copies of one or two antibodies found to be effective at fighting of COVID-19. President Trump was given Regeneron's version when he was hospitalized with COVID-19, and public health experts have high hopes for monoclonal antibody treatments. Eli Lilly and Regeneron are both seeking emergency use authorization from the Food and Drug Administration. Peter Weber